Results 61 to 70 of about 3,887,212 (164)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients [PDF]

, 2022
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated ...
Morticia N. Becx, Brabander, Tessa, Becx, Morticia N., Minczeles, Noémie S., Hofland, Johannes, Johannes Hofland, Tessa Brabander, Noémie S. Minczeles, de Herder, Wouter W., Nonnekens, Julie; id_orcid, Julie Nonnekens, Wouter W. de Herder, Nonnekens, Julie   +12 more
core   +2 more sources

Can acromegaly be controlled in all cases?

Journal of Neuroendocrinology, Volume 38, Issue 8, August 2026.
Abstract Acromegaly is a rare disease, due in most of the cases to a growth hormone (GH)‐secreting pituitary adenoma (PA), namely neuroendocrine tumour (PitNET). The treatment of patients with acromegaly is multimodal and multi‐step, including surgery, medical therapies, and radiotherapy.
Sabrina Chiloiro, Francesco Padovano Sorrentino, Alessandra Vicari, Antonella Giampietro, Pier Paolo Mattogno, Quintino Giorgio D'Alessandris, Rosalinda Calandrelli, Tommaso Tartaglione, Marco Gessi, Simona Gaudino, Laura De Marinis, Guido Rindi, Francesco Doglietto, Antonio Bianchi, Alfredo Pontecorvi   +14 more
wiley   +1 more source

A case of renal primary neuroendocrine tumor (G3) in which 177Lu-PRRT was effective for disease control

Urology Case Reports
Primary renal neuroendocrine tumor (NET) is extremely rare, with no established treatment for advanced cases. We report high-grade (G3) renal NET effectively treated with peptide receptor radionuclide therapy (PRRT).
Saki Inaba, Toshiki Kijima, Mina Takaoka, Toshitaka Uematsu, Kohei Takei, Masahiro Yashi, Kazuyuki Ishida, Taku Aoki, Takao Kamai   +8 more
doaj   +1 more source

Improving image quality in terbium‐161 phantom imaging: Quantitative evaluation of DEW and TEW scatter correction methods

Journal of Applied Clinical Medical Physics, Volume 27, Issue 7, July 2026.
Abstract Background Terbium‐161 (Tb‐161) emits gamma rays and beta radiation, enabling both therapeutic and imaging applications. However, the multiple gamma emissions of 161Tb can affect image quality by increasing the scattering rate during SPECT imaging.
Melek Can, Gamze Çapa Kaya, Gül Gümüşer, Yasemin Parlak   +3 more
wiley   +1 more source

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Endocrine Connections, 2020
Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL).
Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar   +12 more
doaj   +1 more source

Inhibition of SIRT7 Overcomes Radioresistance in Pancreatic Neuroendocrine Tumors by Reactivating MEN1 Expression

Advanced Science, Volume 13, Issue 39, 13 July 2026.
Pancreatic neuroendocrine tumors frequently silence MEN1 through epigenetic mechanisms. Here, SIRT7 recruits DNMT1 to the MEN1 promoter, drives hypermethylation, and enhances DNA repair. Inhibiting SIRT7 restores MEN1, reduces MRN complex abundance, impairs double‐strand break repair, and sensitizes PanNET models to radiation, supporting SIRT7 as a ...
Jianyun Jiang, Yan Wang, Yi Qin, Luohai Chen, Xiaowu Xu, Guixiong Fan, Desheng Jing, Miaoyan Wei, Xianjun Yu, Junfeng Xu, Shunrong Ji, Jie Chen   +11 more
wiley   +1 more source

Peptide receptor radionuclide therapy (PRRT) special issue

DATA AVAILABILITY STATEMENT : Data sharing is not applicable to this article as no new data were created or analyzed in this study.Peptide receptor radionuclide therapy (PRRT), a form of radioligand therapy (RLT), is a well-established treatment in well ...
Navalkissoor, Shaunak, Millar, Robert P.
core   +1 more source

Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Lynch syndrome (LS), a well‐known cancer risk syndrome, is caused by deleterious germline mutations in the mismatch repair genes. LS predispose patients to various types of cancers including colon adenocarcinoma. We discuss the case of a woman with LS who also developed a non‐functioning pancreatic neuroendocrine tumor (P‐NET) following ...
Fateme Salemi, Zahra Sadin, Atefe Barzegari, Seyed Mohammad Reza Mortazavizadeh, Massih Bahar, Motahare Amiri   +5 more
wiley   +1 more source

Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?

, 2015
We report on a 70-year-old man affected by radioiodine-refractory differentiated thyroid cancer (DTC) in whom metastases were treated by peptide receptor radionuclide therapy (PRRT).
PIGNATA, SALVATORE ANTONIO, CAMPENNI', Alfredo, BALDARI, Sergio   +2 more
core   +1 more source

Clinical Utility of 68Ga‐DOTATOC Positron Emission Tomography/Computed Tomography in Evaluating Metastatic Lesions of Clear Cell Renal Cell Carcinoma: A Case Report

IJU Case Reports, Volume 9, Issue 4, July 2026.
ABSTRACT Introduction 68Ga‐DOTATOC positron emission tomography/computed tomography (PET/CT) targets somatostatin receptors (SSTRs) and is an established molecular imaging modality for neuroendocrine tumors (NETs). Although SSTR expression has been reported in renal cell carcinoma (RCC), its clinical utility remains unclear. Case Presentation A 76‐year‐
Yuta Mine, Toru Sakatani, Sho Koyasu, Takashi Ogata, Yuki Teramoto, Akio Sakamoto, Takashi Mizowaki, Yuji Nakamoto, Takashi Kobayashi, Takayuki Goto   +9 more
wiley   +1 more source